AVEO Pharmaceuticals (AVEO) has risen sharply, recording gains of 4.69% in the past 4 weeks. However, the stock has corrected -0.49% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 3.62% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 0.78% and the 50-Day Moving Average is 0.5%. AVEO Pharmaceuticals (NASDAQ:AVEO): stock turned positive on Friday. Though the stock opened at $0.92, the bulls momentum made the stock top out at $1.01 level for the day. The stock recorded a low of $0.9104 and closed the trading day at $0.9851, in the green by 7.37%. The total traded volume for the day was 684,287. The stock had closed at $0.9175 in the previous days trading.
The company Insiders own 5.1% of AVEO Pharmaceuticals shares according to the proxy statements. Institutional Investors own 31.92% of AVEO Pharmaceuticals shares. Also, Piper Jaffray initiates coverage on AVEO Pharmaceuticals (NASDAQ:AVEO) The shares have been rated Overweight. The rating by the firm was issued on May 19, 2016.
AVEO Pharmaceuticals, Inc. (AVEO) is a biopharmaceutical company. The Companys platform has delivered insights into cancer and related disease. The Companys Human Response Platform (HRP) provides insights into cancer and related disease biology and is leveraged in the discovery and clinical development of its therapeutic candidates. The Companys product candidates include AV203, Ficlatuzumab, Tivozanib and AV380. AV203 inhibits the activity of the ErbB3 receptor and its preclinical studies suggest that neuregulin1 (NRG1). Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV380 is for treatment of cachexia. Tivozanib is a potent selective long halflife vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI).